Angiotensin II type 1 receptor antagonists [ARBs (angiotensin receptor blockers)] are indicated for BP (blood pressure)-lowering, renal protection and cardioprotection in patients unable to tolerate ACEIs (angiotensin-converting enzyme inhibitors). A recent meta-analysis revealed an association between ARBs and tumour development, possibly due to enhancement of angiogenesis. However, published evidence is conflicting on the effects of ARBs on angiogenesis or the expansion of the existing vascular network. ARBs have been shown to exert primarily anti-angiogenic effects in basic science studies of cancer, retinopathy, peripheral artery disease and some models of cardiovascular disease. In animal and cellular models of myocardial infarction and stroke, however, ARB administration has been associated with robust increases in vascular density and improved recovery. The aim of the present review is to examine the angiogenic effects of ARBs in animal and cellular models of relevant disease states, including proposed molecular mechanisms of action of ARBs and the clinical consequences of ARB use.
Skip Nav Destination
Article navigation
Review Article|
December 22 2010
Angiotensin receptor blockers and angiogenesis: clinical and experimental evidence
Lauren M. Willis;
Lauren M. Willis
1Program in Clinical and Experimental Therapeutics, University of Georgia College of Pharmacy, Charlie Norwood VA Medical Center, Augusta, GA 30912, U.S.A.
Search for other works by this author on:
Azza B. El-Remessy;
Azza B. El-Remessy
1Program in Clinical and Experimental Therapeutics, University of Georgia College of Pharmacy, Charlie Norwood VA Medical Center, Augusta, GA 30912, U.S.A.
Search for other works by this author on:
Payaningal R. Somanath;
Payaningal R. Somanath
1Program in Clinical and Experimental Therapeutics, University of Georgia College of Pharmacy, Charlie Norwood VA Medical Center, Augusta, GA 30912, U.S.A.
Search for other works by this author on:
David L. Deremer;
David L. Deremer
1Program in Clinical and Experimental Therapeutics, University of Georgia College of Pharmacy, Charlie Norwood VA Medical Center, Augusta, GA 30912, U.S.A.
Search for other works by this author on:
Susan C. Fagan
1Program in Clinical and Experimental Therapeutics, University of Georgia College of Pharmacy, Charlie Norwood VA Medical Center, Augusta, GA 30912, U.S.A.
Correspondence: Professor Susan C. Fagan (email [email protected]).
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
July 22 2010
Revision Received:
October 21 2010
Accepted:
November 18 2010
Online ISSN: 1470-8736
Print ISSN: 0143-5221
© The Authors Journal compilation © 2011 Biochemical Society
2011
Clin Sci (Lond) (2011) 120 (8): 307–319.
Article history
Received:
July 22 2010
Revision Received:
October 21 2010
Accepted:
November 18 2010
Citation
Lauren M. Willis, Azza B. El-Remessy, Payaningal R. Somanath, David L. Deremer, Susan C. Fagan; Angiotensin receptor blockers and angiogenesis: clinical and experimental evidence. Clin Sci (Lond) 1 April 2011; 120 (8): 307–319. doi: https://doi.org/10.1042/CS20100389
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Biochemical Society Member Sign in
Sign InSign in via your Institution
Sign in via your InstitutionGet Access To This Article
Open Access for all
We offer compliant routes for all authors from 2025. With library support, there will be no author nor reader charges in 5 journals. Check here |
![]() |